Thyroid Scintigraphy
On this page
Direct answer
Thyroid scintigraphy classifies thyrotoxicosis and characterises nodules by uptake pattern. Technetium-99m pertechnetate (trapped by the gland but not organified) or iodine-123 is imaged 20-30 minutes or several hours after injection respectively: Graves disease shows diffuse intense uptake, toxic multinodular goitre shows patchy uptake with hot nodules suppressing the rest, and destructive thyroiditis — subacute, postpartal, amiodarone-induced type 2 — shows near-absent uptake, the single most therapeutic distinction in thyrotoxicosis because thyroiditis gets steroids or observation, not antithyroid drugs or radioiodine. Hot nodules are autonomous and almost never malignant; cold nodules require ultrasound and fine-needle aspiration. Iodine-131, a beta and gamma emitter with an eight-day half-life, treats hyperthyroidism and differentiated thyroid cancer but is absolutely contraindicated in pregnancy and breastfeeding.
What you must remember
- Tracer logic: pertechnetate is trapped by the sodium-iodide symporter but not organified — hence the rare "discrepancy nodule" that traps pertechnetate yet is cold on iodine imaging; iodine-123 is organified and more physiological but costlier.
- Thyrotoxicosis decision tree: diffuse uptake equals Graves; patchy lumpy uptake equals toxic multinodular goitre; a single hot focus with suppressed background equals toxic adenoma; uptake near zero equals thyroiditis (or exogenous hormone, or recent iodine load).
- Nodule rule: hot nodules are almost never malignant; cold nodules carry a roughly 5-15% malignancy risk in a palpable nodule and route to ultrasound with fine-needle aspiration.
- Amiodarone thyrotoxicosis: type 1 (iodine-induced excess synthesis) shows increased uptake; type 2 (destructive thyroiditis) shows near-none — the split decides thionamide versus steroids.
- Radioiodine-131: half-life about 8 days, beta emission for therapy plus 364 keV gamma for imaging; treats Graves, toxic nodular goitre and differentiated thyroid cancer ablation.
- Pregnancy and lactation: absolute contraindication to I-131; a pregnancy test precedes therapy, and breastfeeding must stop (with a discard interval) before radioiodine administration.
- Superscan clue in thyroid cancer: post-thyroidectomy I-131 whole-body scanning surveys for residual, nodal and distant disease, with stimulated thyroglobulin as its biochemical partner.
- Technique detail: pertechnetate imaging at about 20-30 minutes; withholding of thyroid hormone and iodine-containing drugs (amiodarone, recent contrast) is a prerequisite for valid uptake measurement.
Sorting one thyrotoxic patient
A 34-year-old woman, six weeks postpartum, presents with palpitations, tremor and a mildly tender gland; T4 is high and TSH suppressed. The clinical fork is Graves disease versus postpartum (lymphocytic) thyroiditis, and the treatments are opposites — antithyroid drugs and perhaps radioiodine versus observation with beta-blockers. Scintigraphy with pertechnetate shows a gland almost invisible against background: uptake under 1-2%. That single image ends the argument — destructive thyroiditis releasing preformed hormone, managed expectantly, often transiting to a hypothyroid phase. Now replay the same scene with a diffuse, intensely hot gland, a bruit and orbitopathy: Graves, and the discussion moves to the duration of thionamides versus definitive radioiodine, with the parenthood caveat that I-131 is deferred in pregnancy planning and after a recent breastfeeding period. The thyroid uptake number, not the hormone panel alone, is what pivots management — which is why boards pair a "low-uptake thyrotoxicosis" stem with thyroiditis and a "high-uptake" stem with Graves as reliably as sunrise.
The uptake-number viva
Reading the hormone pattern as sufficient is the core error — thyrotoxicosis biochemistry cannot distinguish synthesis excess from destructive release; only uptake imaging (or TSH-receptor antibodies) can. The second slip is cold-nodule overreaction: a cold area on a scan is common (cysts, colloid nodules, haemorrhage compete with malignancy) and mandates ultrasound, not immediate surgery; scintigraphy triages, ultrasound and cytology diagnose. Third, the pertechnetate-versus-iodine subtlety: a nodule that appears warm on pertechnetate can be cold on iodine because trapping without organisation is possible — a classic physiological viva question. In Indian practice, remember the iodine-deficiency hinterland: multinodular goitres are common, and a dominant cold area within a long-standing goitre deserves scrutiny for malignancy rather than dismissal as degeneration.
Frequently asked questions
What uptake pattern distinguishes Graves disease from thyroiditis?
Graves shows diffuse intense glandular uptake, while destructive thyroiditis (subacute, postpartum, amiodarone type 2) shows near-absent uptake because the gland is leaking, not synthesising, hormone.
Why are hot thyroid nodules rarely malignant?
Autonomously functioning nodules suppress TSH, and the hyperstimulatory environment needed for most differentiated carcinomas is absent — malignancy risk in a truly hot nodule is under about 1-4%.
Which tracer is preferred for thyroid imaging and why?
Iodine-123 for physiological uptake imaging (organified, lower dose) and technetium-99m pertechnetate for routine convenience (available, cheap, 20-30 minute imaging), with the caveat that pertechnetate is trapped but not organified.
What are the two types of amiodarone-induced thyrotoxicosis on scanning?
Type 1, iodine-induced hormone excess, shows normal or increased uptake; type 2, destructive thyroiditis, shows suppressed uptake — separating thionamide therapy from glucocorticoids.
When is radioiodine-131 contraindicated?
In pregnancy and breastfeeding, absolutely; also deferred with recent iodinated contrast exposure or antithyroid drug loading that would block uptake, and used cautiously where ophthalmopathy is active in Graves.